|Bid||52.15 x 1800|
|Ask||56.10 x 800|
|Day's Range||50.00 - 53.14|
|52 Week Range||34.53 - 96.59|
|Beta (3Y Monthly)||1.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 19, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||60.75|
Spark Therapeutics (ONCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Spark Therapeutics (ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Feb. 19, 2019, at 8:30 a.m. ET to discuss corporate and financial results for the year that ended Dec. 31, 2018, and recent business highlights. To access a live audio webcast, please visit the “Investors” section of the Spark Therapeutics website at www.sparktx.com. A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 1089969, or by visiting the “Investors” section of the Spark Therapeutics website at www.sparktx.com.
Gene therapy player Uniqure could garner takeover interest, an analyst said Friday after the biotech unveiled promising data in hemophilia B. Uniqure rivals Pfizer and Spark Therapeutics.
Spark Therapeutics Inc NASDAQ/NGS:ONCEView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for ONCE with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting ONCE. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ONCE totaled $2.61 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The biotech world is feverishly awaiting the FDA's potential approval of a gene therapy called Zolgensma, a spinal muscular atrophy treatment, that is expected from Novartis in May.
Novartis (NVS) misses estimates in Q4 as generic unit continues to face challenging business conditions. The outlook for 2019 didn't impress investors either.
Spark Therapeutics (ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today the presentation of preclinical data for SPK-3006 for Pompe disease and SPK-1001 for CLN2 disease, a form of Batten disease, on Wednesday, Feb. 6, 2019, at the 15th Annual WORLDSymposium™ in Orlando, FL. Giuseppe Ronzitti, Ph.D., team leader at Genethon and researcher at the French National Institute of Health and Medical Research (INSERM), will present preclinical data for SPK-3006, an investigational liver-directed adeno-associated viral (AAV) gene therapy for Pompe disease, at 8:45am ET.
How far off is Spark Therapeutics, Inc. (NASDAQ:ONCE) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is Read More...
Who Is Eyeing Sangamo Therapeutics Now?(Continued from Prior Part)Earnings trends In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.
Who Is Eyeing Sangamo Therapeutics Now?Stock performance On December 27, Sangamo Therapeutics (SGMO) stock price closed at $10.59, which is a ~1.58% decline from its prior day close of $10.76 on December 26, 2018.
PHILADELPHIA, Jan. 02, 2019 -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic.
Novartis (NVS) gets a boost from strong performance of new drugs. Strategic acquisitions to foray into promising areas has also boosted investor sentiment.
Novartis (NVS) looks to buy French company, CellforCure to expand manufacturing capacity for innovative cell and gene therapies.
Spark Therapeutics (ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced updated preliminary data on the first 12 participants in the ongoing Phase 1/2 clinical trial of investigational SPK-8011 in hemophilia A. These data were presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego by Principal Investigator Lindsey A. George, M.D., assistant professor of pediatrics, The Perelman School of Medicine, University of Pennsylvania and attending physician in the Division of Hematology at Children’s Hospital of Philadelphia. The 12 participants in the Phase 1/2 trial received a single administration of investigational SPK-8011, including two at a dose of 5x1011 vector genomes (vg)/kg body weight, three at a dose of 1x1012 vg/kg and seven at a dose of 2x1012 vg/kg.
Jeffrey Marrazzo, Spark Therapeutics CEO, joins 'Squawk Box' to discuss how his company is making breakthroughs in gene therapy and the fight to cure hemophilia.